Yahoo · Aug 7, 2026
Context drops bispecific T-cell engager on cost-cutting initiative
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
CN
NASDAQ · CNTX
Context Therapeutics Inc.
Healthcare · Biotechnology
$0.50
Down-$0.02 (-3.77%)
Updated Aug 22, 2026, 8:59 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 94.64M
- P/E ratio
- -2.87
- Dividend yield
- 0.00%
- 52-week range
- $0.43 – $3.62
- Volume
- 1.75M
- Avg. volume
- 402.34K
Price performance
CNTX price history
1M range · 21 trading sessions · Daily adjusted prices
CNTX closed at $0.50 after 21 trading sessions, down 18.56% for the selected period.
- Last close
- $0.50
- Period change
- -18.56%
- Period low
- $0.45
- Period high
- $0.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.5269 | $0.5469 | $0.50 | $0.5001 | 1.75M |
| Aug 20, 2026 | $0.4858 | $0.5226 | $0.483 | $0.5197 | 1.99M |
| Aug 19, 2026 | $0.4852 | $0.50 | $0.45 | $0.4875 | 4.18M |
| Aug 18, 2026 | $0.5304 | $0.5304 | $0.49 | $0.4965 | 3.34M |
| Aug 17, 2026 | $0.53 | $0.535 | $0.5156 | $0.5303 | 925.62K |
| Aug 14, 2026 | $0.4978 | $0.535 | $0.49 | $0.5229 | 1.26M |
| Aug 13, 2026 | $0.4679 | $0.51 | $0.4675 | $0.5064 | 1.59M |
| Aug 12, 2026 | $0.4775 | $0.48 | $0.4522 | $0.4699 | 1.36M |
| Aug 11, 2026 | $0.4655 | $0.474 | $0.4529 | $0.4658 | 1.22M |
| Aug 10, 2026 | $0.4895 | $0.49 | $0.432 | $0.4523 | 2.32M |
| Aug 7, 2026 | $0.5099 | $0.5287 | $0.48 | $0.484 | 2.43M |
| Aug 6, 2026 | $0.5049 | $0.5399 | $0.49 | $0.504 | 4.34M |
| Aug 5, 2026 | $0.63 | $0.6949 | $0.616 | $0.693 | 3.34M |
| Aug 4, 2026 | $0.6031 | $0.6387 | $0.5999 | $0.6218 | 945.55K |
| Aug 3, 2026 | $0.6195 | $0.6329 | $0.59 | $0.6041 | 1.48M |
| Jul 31, 2026 | $0.60 | $0.6149 | $0.579 | $0.5994 | 964.92K |
| Jul 30, 2026 | $0.6169 | $0.6299 | $0.6001 | $0.6073 | 1.01M |
| Jul 29, 2026 | $0.59 | $0.62 | $0.5782 | $0.617 | 1.21M |
| Jul 28, 2026 | $0.62 | $0.62 | $0.572 | $0.5906 | 2.22M |
| Jul 27, 2026 | $0.6132 | $0.65 | $0.6018 | $0.6223 | 1.73M |
| Jul 24, 2026 | $0.6088 | $0.6252 | $0.5602 | $0.6141 | 2.09M |
Latest CNTX news
The latest Smart Investors Daily articles mentioning CNTX.
Stock researchCompany · Overview
CNTX research
Overview
Company profile and research snapshot.
Company profile
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $5.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 16, 2026 | Maxim Group | Buy | — |
| Mar 24, 2026 | D. Boral Capital | Buy | — |
| Mar 24, 2026 | Piper Sandler | Overweight | — |
| Mar 24, 2026 | Guggenheim | Buy | — |
| Dec 22, 2025 | Jones Trading | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 6, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) stock rose
Benzinga · Aug 6, 2026
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move
Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.
Yahoo · Aug 5, 2026
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027 PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for t
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
